{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-25-000002","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.290831+00:00","generated_at":"2026-05-28T02:55:55.305510+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M","bullets":["Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).","U.S. revenue $101.6M (+14%), international $22.7M (+28%) in Q4.","FY2024 revenue $465.3M (+17%); expects adj. EBITDA $26M-$29M and adj. EPS loss $0.74-$0.80.","2025 guidance: revenue $517M-$527M, adj. EBITDA $40M-$44M, modest cash flow generation.","Analyst & Investor Day scheduled for March 26, 2025 at Mason, Ohio headquarters."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-25-000002","json":"https://secwatch.observer/filing/0001323885-25-000002.json","markdown":"https://secwatch.observer/filing/0001323885-25-000002.md","text":"https://secwatch.observer/filing/0001323885-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388525000002/0001323885-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388525000002/atrc-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:55:55.305510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}